Evidence map›Paper›PMID 19274084›Full record

ArticlePloS one2009

Transdermal influenza immunization with vaccine-coated microneedle arrays.

Dimitrios G Koutsonanos, Maria del Pilar Martin, Vladimir G Zarnitsyn, Sean P Sullivan, Richard W Compans, Mark R Prausnitz, Ioanna Skountzou

Abstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Progress in microneedle array patch (MAP) for vaccine delivery.Human vaccines & immunotherapeutics · 2021
    Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dimitrios G KoutsonanosDepartment of Microbiology & Immunology and Emory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Maria del Pilar Martin
Vladimir G Zarnitsyn
Sean P Sullivan
Richard W Compans
Mark R Prausnitz
Ioanna Skountzou

Funding

Self-administered microneedle patches for influenza vaccinesU01AI074579 · NIAID · EMORY UNIVERSITY · PI COMPANS, RICHARD W · 2007 to 2011
$7.7M
Microneedle-based immunization against pandemic influenzaR01EB006369 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI PRAUSNITZ, MARK R. · 2007 to 2011
$3.6M
NIAID NIH HHS AI074579NIAID NIH HHS U01 AI074579NIBIB NIH HHS EB006369NIBIB NIH HHS R01 EB006369
6 · The paper itself

Abstract

backgroundInfluenza is a contagious disease caused by a pathogenic virus, with outbreaks all over the world and thousands of hospitalizations and deaths every year. Due to virus antigenic drift and short-lived immune responses, annual vaccination is required. However, vaccine coverage is incomplete, and improvement in immunization is needed. The objective of this study is to investigate a novel method for transdermal delivery using metal microneedle arrays (MN) coated with inactivated influenza virus to determine whether this route is a simpler and safer approach than the conventional immunization, capable to induce robust immune responses and confer protection against lethal virus challenge. METHODOLOGY/PRINCIPAL

findingsInactivated A/Aichi/2/68 (H3N2) influenza virus was coated on metal microneedle arrays and applied to mice as a vaccine in the caudal dorsal skin area. Substantial antibody titers with hemagglutination inhibition activity were detected in sera collected two and four weeks after a single vaccine dose. Challenge studies in mice with 5 x LD(50) of mouse adapted Aichi virus demonstrated complete protection. Microneedle vaccination induced a broad spectrum of immune responses including CD4+ and CD8+ responses in the spleen and draining lymph node, a high frequency of antigen-secreting cells in the lung and induction of virus-specific memory B-cells. In addition, the use of MN showed a dose-sparing effect and a strong Th2 bias when compared to an intramuscular (IM) reference immunization. CONCLUSIONS/SIGNIFICANCE: The present results show that delivery of inactivated influenza virus through the skin using metal microneedle arrays induced strong humoral and cellular immune responses capable of conferring protection against virus challenge as efficiently as intramuscular immunization, which is the standard vaccination route. In view of the convenience of delivery and the potential for self-administration, vaccine-coated metal microneedles may provide a novel and highly effective immunization method.

Indexed as

Administration, CutaneousNeedlesAnimalsAntibody FormationEquipment DesignImmunity, CellularInfluenza A Virus, H3N2 SubtypeInfluenza VaccinesMiceVaccinationInfluenza Vaccines

Identifiers

PMID19274084
PMCPMC2651574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.